Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib

por Atrash, S, Tullos, A, Panozzo, S, Bhutani, M, Van Rhee, F, Barlogie, B, Usmani, S Z
Publicado 2015

P1140: TIME TO TUMOR, SYMPTOMATIC AND LABORATORY RESPONSES FOLLOWING SILTUXIMAB TREATMENT IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE

por van Rhee, F., Rosenthal, A., Kanhai, K., Martin, R., Nishimura, K., Hoering, A., Fajgenbaum, D.
Publicado 2022

Role of Bruton's tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells

por Bam, R, Venkateshaiah, S U, Khan, S, Ling, W, Randal, S S, Li, X, Zhang, Q, van Rhee, F, Barlogie, B, Epstein, J, Yaccoby, S
Publicado 2014

Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma

por Heuck, C J, Qu, P, van Rhee, F, Waheed, S, Usmani, S Z, Epstein, J, Zhang, Q, Edmondson, R, Hoering, A, Crowley, J, Barlogie, B
Publicado 2014

Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma

por Khan, R, Apewokin, S, Grazziutti, M, Yaccoby, S, Epstein, J, van Rhee, F, Rosenthal, A, Waheed, S, Usmani, S, Atrash, S, Kumar, S, Hoering, A, Crowley, J, Shaughnessy, J D, Barlogie, B
Publicado 2015

Flow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of...

por Papanikolaou, X, Rosenthal, A, Dhodapkar, M, Epstein, J, Khan, R, van Rhee, F, Jethava, Y, Waheed, S, Zangari, M, Hoering, A, Crowley, J, Alapat, D, Davies, F, Morgan, G, Barlogie, B
Publicado 2016

P925: IMPACT OF PRIOR TREATMENT EXPOSURE ON THE EFFECTIVENESS OF IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED IN ROUTINE CLINICAL PR...

por Lee, H. C., Ramasamy, K., Macro, M., Davies, F. E., Abonour, R., van Rhee, F., Hungria, V. T., Puig, N., Ren, K., Silar, J., Enwemadu, V., Cherepanov, D., Stull, D. M., Leleu, X.
Publicado 2022

Inhibiting MEK in MAPK pathway-activated myeloma

por Heuck, C J, Jethava, Y, Khan, R, van Rhee, F, Zangari, M, Chavan, S, Robbins, K, Miller, S E, Matin, A, Mohan, M, Ali, S M, Stephens, P J, Ross, J S, Miller, V A, Davies, F, Barlogie, B, Morgan, G
Publicado 2016

The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma

por Papanikolaou, X, Alapat, D, Rosenthal, A, Stein, C, Epstein, J, Owens, R, Yaccoby, S, Johnson, S, Bailey, C, Heuck, C, Tian, E, Joiner, A, van Rhee, F, Khan, R, Zangari, M, Jethava, Y, Waheed, S, Davies, F, Morgan, G, Barlogie, B
Publicado 2015

Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma

por Jethava, Y, Mitchell, A, Zangari, M, Waheed, S, Schinke, C, Thanendrarajan, S, Sawyer, J, Alapat, D, Tian, E, Stein, C, Khan, R, Heuck, C J, Petty, N, Avery, D, Steward, D, Smith, R, Bailey, C, Epstein, J, Yaccoby, S, Hoering, A, Crowley, J, Morgan, G, Barlogie, B, van Rhee, F
Publicado 2016

Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma

por Jethava, Y, Mitchell, A, Zangari, M, Waheed, S, Schinke, C, Thanendrarajan, S, Sawyer, J, Alapat, D, Tian, E, Stein, C, Khan, R, Heuck, C J, Petty, N, Avery, D, Steward, D, Smith, R, Bailey, C, Epstein, J, Yaccoby, S, Hoering, A, Crowley, J, Morgan, G, Barlogie, B, van Rhee, F
Publicado 2016

Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing

por Rasche, L., Chavan, S. S., Stephens, O. W., Patel, P. H., Tytarenko, R., Ashby, C., Bauer, M., Stein, C., Deshpande, S., Wardell, C., Buzder, T., Molnar, G., Zangari, M., van Rhee, F., Thanendrarajan, S., Schinke, C., Epstein, J., Davies, F. E., Walker, B. A., Meissner, T., Barlogie, B., Morgan, G. J., Weinhold, N.
Publicado 2017

Combination of Flow Cytometry and Functional Imaging for Monitoring of Residual Disease in Myeloma

por Rasche, L, Alapat, D, Kumar, M, Gershner, G, McDonald, J, Wardell, C.P, Samant, R, Van Hemert, R, Epstein, J, Williams, A.F, Thanendrarajan, S, Schinke, C, Bauer, M, Ashby, C, Tytarenko, R.G, van Rhee, F, Walker, B.A, Zangari, M, Barlogie, B, Davies, F.E, Morgan, G.J, Weinhold, N
Publicado 2018

Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker

por Chavan, S S, He, J, Tytarenko, R, Deshpande, S, Patel, P, Bailey, M, Stein, C K, Stephens, O, Weinhold, N, Petty, N, Steward, D, Rasche, L, Bauer, M, Ashby, C, Peterson, E, Ali, S, Ross, J, Miller, V A, Stephens, P, Thanendrarajan, S, Schinke, C, Zangari, M, van Rhee, F, Barlogie, B, Mughal, T I, Davies, F E, Morgan, G J, Walker, B A
Publicado 2017